Sonic Media Corp. Changes Its Name to Larrea Biosciences Corporation and Its NASDAQ Trading Symbol to LRRA to Reflect New Core Business and Products

Larrea Biosciences (NASDAQ symbol: LRRA) has officially changed its corporate name and trading symbol to reflect its core business model, the commercial development and marketing of pharmaceutical and consumer products based on patented extracts of the plant, Larrea trdentata. The Company has also retained LDMB Advisors, Inc., Chartered Accountants to conduct necessary financial audits for Larrea Biosciences Corporation.

Carson City, NV (PRWEB) July 27, 2004 -- Larrea Biosciences (NASDAQ symbol: LRRA) has officially changed its corporate name and trading symbol to reflect its core business model, the commercial development and marketing of products based on patented extracts of the plant, Larrea trdentata. The Company has also retained LDMB Advisors, Inc., Chartered Accountants to conduct necessary financial audits for Larrea Biosciences Corporation.

Larrea is a 12,000 year-old desert shrub that has been shown to be highly effective against the herpes class of viruses. The plant has long been used in folk medicine by Native Americans and European settlers to treat conditions ranging from digestive disorders and rheumatism to venereal disease, bronchitis and the common cold. Studies have shown that the Larrea plant contains two kinds of compounds with potent antiviral capabilities, including flavonoids and lignans. These compounds also function as antioxidants.

Larrea represents a large, untapped natural resource that has extensive commercial development opportunity. As well as the long history of medicinal use by Native Americans of the Southwestern U.S., the utility of the plant extract is substantiated byte many years of modern scientific research, which supports the use of the plant as an important ingredient in health and consumer products.

Larrea Biosciences has purchased four U.S. Patents that relate to the production of extracts from Larrea tridentata and their utility in a variety of products to address viral and inflammatory conditions. The Companys current licensee for this technology, LarreaRx, Inc., manufactures and distributes Larrea-based health products throughout retail and direct marketing channels. Products are sold in retail outlets under the tradename Virox and through direct marketing channels under the tradename Shegoi. Virastatin gives rise to Larrea-based products that are readily absorbed into the digestive tract for maximum results and optimal safety.

Each of the brand lines currently consist of a dietary supplement, a topical cold sore lotion and a penetrating spray for the management of health. Virox products are distributed throughout the US through Tree of Life, Untied Natural Foods Incorporated, Select Nutrition and selected Whole Foods outlets. Puresource Inc. and Asenda Pharmaceuticals represent the products in Canada. Consumers can purchase Virox through Whole Foods, Akins, Chamberlains, Vitamin Cottage, selected Vitamin World and other health food retailers in the US. Safeway, London Drugs, Save-On Foods, Whole Foods, Capers, Overwaitea, Thrifty Foods and other health food stores retail the products in Canada.

About Larrea Biosciences Corporation

Larrea Biosciences Corporation is engaged in the industrial field of applied biosciences research and development. The Company also participates in the retail sector with worldwide distribution of nutriceutical and cosmeceutical products. The Company currently obtains the revenues from a patented ingredient that is derived from the oldest living plant on earth, Larrea tridentata and a number of consumer products containing the ingredient. The ingredient and the products containing it are currently protected by four United States patents with additional U.S. and international patents pending. Virastatin-based products have demonstrated excellent results in treating herpes virus conditions, including cold sores, genital herpes and shingles; inflammatory conditions, including arthritis, sinusitis, gastrointestinal disorders, eczema, psoriasis; and various microbial and fungal conditions. The Company plans to become the world leader in the industrialization and commercialization of Larrea for a wide range of health and consumer products.

Forward-Looking Statement

Any statements contained herein that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Potential factors could cause actual results to differ materially from those expressed or implied by such statements. Information on the potential factors that could affect the Companys actual results of operations is included in its filings with the Securities and Exchange Commission. These risks may be further discussed in periodic reports and registration statements to be filed by the Company from time to time with the Securities and Exchange Commission in the future.

# # #